{
  "abstract": "Willem van Gool and colleagues argue that moves to use blood biomarkers in clinical practice or population screening are inappropriate without evidence on outcomes important to patients and carers",
  "authors": [
    {
      "affiliations": [
        "Department of Public and Occupational Health, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands"
      ],
      "name": "Willem A Van Gool"
    },
    {
      "affiliations": [
        "Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud, University Medical Center, Nijmegen, Netherlands"
      ],
      "name": "J A Floria Siebrand"
    },
    {
      "affiliations": [
        "Department of Psychiatry, Cambridge Public Health, University of Cambridge, UK"
      ],
      "name": "Carol Brayne"
    },
    {
      "affiliations": [
        "Department of Medicine, University of Washington, Seattle, USA"
      ],
      "name": "Eric B Larson"
    },
    {
      "affiliations": [
        "Department of Public and Occupational Health, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands",
        "Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud, University Medical Center, Nijmegen, Netherlands"
      ],
      "name": "Edo Richard"
    }
  ],
  "title": "Evidence gap in blood biomarkers for Alzheimer’s disease",
  "uid": "a8029aa9-f359-5779-b4cf-6b65a021d439"
}